Scholarlink

<p>Optimal management for isolated para-aortic lymph node (PALN) recurrence from colorectal cancer (CRC) remains undefined. We evaluated the efficacy and safety of radiotherapy (RT) for this indication. A PRISMA-compliant systematic review and meta-analysis (PROSPERO CRD42025634494) was conducted using four databases through April 2025. Pooled locoregional progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were estimated using a random-effects model. Five retrospective studies (<i>n</i> = 220) were included. Pooled 1- and 3-year LPFS were 84% (95% CI, 78–89%) and 69% (62–76%), respectively. Pooled 1- and 3-year PFS were 54% (42–65%) and 22% (14–32%). Pooled 1- and 3-year OS were 91% (87–95%) and 64% (54–73%). Primary colon tumors were associated with poorer survival outcomes, while female sex predicted improved 3-year PFS. Severe (grade ≥ 3) acute and chronic toxicities were low (7.7% and 0.5%, respectively). Modern RT for PALN recurrence from CRC provides favorable local control with acceptable toxicity. With a 3-year OS of 64%, RT offers a potential survival benefit for carefully selected patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolated para-aortic lymph node recurrence from colorectal cancer treated by radiotherapy: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月4日

查看全文
  • Seok-Joo Chun,
  • Hyunkyung Kim,
  • Jiyun Jung,
  • Sun Hyun Bae,
  • Mi-Sook Kim

摘要

Optimal management for isolated para-aortic lymph node (PALN) recurrence from colorectal cancer (CRC) remains undefined. We evaluated the efficacy and safety of radiotherapy (RT) for this indication. A PRISMA-compliant systematic review and meta-analysis (PROSPERO CRD42025634494) was conducted using four databases through April 2025. Pooled locoregional progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were estimated using a random-effects model. Five retrospective studies (n = 220) were included. Pooled 1- and 3-year LPFS were 84% (95% CI, 78–89%) and 69% (62–76%), respectively. Pooled 1- and 3-year PFS were 54% (42–65%) and 22% (14–32%). Pooled 1- and 3-year OS were 91% (87–95%) and 64% (54–73%). Primary colon tumors were associated with poorer survival outcomes, while female sex predicted improved 3-year PFS. Severe (grade ≥ 3) acute and chronic toxicities were low (7.7% and 0.5%, respectively). Modern RT for PALN recurrence from CRC provides favorable local control with acceptable toxicity. With a 3-year OS of 64%, RT offers a potential survival benefit for carefully selected patients.